Coherus BioSciences Net Income 2013-2021 | CHRS

Coherus BioSciences net income from 2013 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Coherus BioSciences Annual Net Income
(Millions of US $)
2020 $132
2019 $90
2018 $-209
2017 $-238
2016 $-127
2015 $-223
2014 $-87
2013 $-54
2012 $-33
2011 $-2
2010 $-54
2009 $-78
2008 $-255
2007 $-88
2006 $109
2005 $99
Coherus BioSciences Quarterly Net Income
(Millions of US $)
2021-06-30 $-30
2021-03-31 $-173
2020-12-31 $10
2020-09-30 $28
2020-06-30 $59
2020-03-31 $36
2019-12-31 $39
2019-09-30 $47
2019-06-30 $24
2019-03-31 $-20
2018-12-31 $-63
2018-09-30 $-59
2018-06-30 $-44
2018-03-31 $-44
2017-12-31 $-49
2017-09-30 $-59
2017-06-30 $-55
2017-03-31 $-75
2016-12-31 $-76
2016-09-30 $84
2016-06-30 $-70
2016-03-31 $-65
2015-12-31 $-52
2015-09-30 $-71
2015-06-30 $-59
2015-03-31 $-41
2014-12-31 $-29
2014-09-30 $-8
2014-06-30 $-25
2014-03-31 $-25
2013-12-31
2013-09-30 $-21
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.305B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.527B 8.42
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.880B 20.12
Biohaven Pharmaceutical Holding (BHVN) United States $8.436B 0.00
Emergent Biosolutions (EBS) United States $2.707B 6.53
Arcus Biosciences (RCUS) United States $2.445B 0.00
Myovant Sciences (MYOV) United Kingdom $1.866B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.750B 0.00
Zymeworks (ZYME) Canada $1.118B 0.00
Ambrx Biopharma (AMAM) United States $0.483B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76